Anixa Biosciences（股票代码：ANIX）宣布，其CAR-T（嵌合抗原受体T细胞）疗法已获得美国采纳名称委员会（United States Adopted Names Council, USAN）对非专利名称的批准。这一重要监管里程碑标志着该疗法在通往未来商业化的道路上迈出了关键一步。CAR-T疗法作为一种创新的癌症治疗方法，通过改造患者自身的T细胞来靶向并摧毁癌细胞，近年来在肿瘤治疗领域展现出巨大潜力。此次非专利名称的获批，不仅为Anixa Biosciences后续的临床试验、专利申请以及市场推广奠定了基础，也进一步增强了投资者对公司研发管线进展的信心。公司表示，将继续推进该疗法的临床开发工作，并积极筹备后续的商业化战略。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.